

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

ZNF268 RABBIT PAB

Cat.#: S218049

Product Name: Anti-ZNF268 Rabbit Polyclonal Antibody

Synonyms: HZF3

UNIPROT ID: Q14587 (Gene Accession - BC110542)

Background: Zinc-finger proteins contain DNA-binding domains and have a wide variety of functions, most of which encompass some form of transcriptional activation or repression. The majority of zinc-finger proteins contain a krueppel-type DNA binding domain and a KRAB domain, which is thought to interact with KAPI, thereby recruiting histone modifying proteins. Zinc finger protein 268 (ZNF268), also known as zinc finger protein 3 or HZF3, is a 947 amino acid protein belonging to the krueppel C2H2-type zinc-finger protein family. ZNF268 contains 24 C2H2-type zinc fingers and one KRAB domain. Localized to the nucleus, ZNF268 is involved in transcriptional regulation and is highly expressed in three to five week old embryos. ZNF268 has been implicated in human leukemia, due to the identification of an alternatively spliced form in leukemia patients. Two named isoforms of ZNF268 exist as a result of alternative splicing events.

Immunogen: Fusion protein of human ZNF268

Applications: ELISA, IHC

Recommended Dilutions: IHC: 40-250; ELISA: 2000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human


Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Epigenetics and Nuclear Signaling

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 218049(ZNF268 Antibody) at a dilution of 1/50(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 218049(Anti-ZNF268 Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010